#United States #Novo Nordisk #GLP-1 #Plainsboro #Wegovy®

Wegovy® Reaches an Impressive Milestone: Over Three Million Prescriptions

On June 7, 2026, Novo Nordisk announced a remarkable achievement for its weight management medication, Wegovy® (semaglutide) tablets 25 mg. In just a little over five months since its launch on January 5, 2026, the number of Wegovy® prescriptions in the US surpassed three million, creating a buzz in the pharmaceutical industry. This accounts for an astonishing frequency of one prescription filled approximately every five seconds!

A New Era in Obesity Treatment

Wegovy® is making waves by largely attracting individuals who are new to GLP-1 therapies, offering a fresh approach that broadens the obesity treatment landscape. With a significant 80% of new prescriptions going to those unfamiliar with such treatments, Wegovy® is not merely replacing existing therapies but is reinventing how obesity is managed.

Rapid Adoption and Market Impact

The uptake of Wegovy® has been nothing short of extraordinary. It reached its first million prescriptions within just 12 weeks of being available, and an additional two million prescriptions exploded onto the scene in a subsequent 10 weeks. This growth places Wegovy® among the best pharmaceutical launches in US history based on volume.

Jamey Millar, Executive Vice President of US Operations at Novo Nordisk, emphasized the importance of Wegovy® in aiding adults with obesity in achieving significant weight loss, particularly when combined with diet and exercise. Furthermore, the FDA has approved Wegovy® for reducing the risk of serious cardiovascular events, such as heart attacks and strokes, in adults with obesity who also have known heart disease, adding another layer of distinction to this medication.

Commitment to Addressing Obesity

Novo Nordisk is deeply committed to addressing obesity as a global public health crisis. This commitment is evident through their presence at the American Diabetes Association’s 2026 Scientific Sessions, where they aim to engage with patients, healthcare providers, and stakeholders, sharing data and insights while also listening to the needs of those affected by obesity.

Moreover, Wegovy® stands out in the current market as the most widely prescribed obesity medication for those starting a new weight management therapy, demonstrating a shift in how obesity treatments are perceived and utilized.

Cost Accessibility Initiatives

In its effort to boost accessibility, Novo Nordisk launched various initiatives allowing patients with commercial insurance coverage to access Wegovy® for as low as $25 per month through savings programs. Additionally, starting July 1, 2026, Medicare beneficiaries living with obesity will be able to obtain Wegovy® at a nominal copayment of $50 monthly. This initiative marks a significant step toward making effective obesity treatments more reachable for a larger demographic.

As Wegovy® continues to find its footing in the market, Novo Nordisk is not resting on its laurels; they are actively preparing to introduce Wegovy® outside the US by the latter half of 2026, with initial launches planned for the United Arab Emirates.

Ongoing Research and Future Prospects

At the ADA 2026 event, Novo Nordisk is expected to present a wealth of clinical data regarding Wegovy® and its implications for individuals suffering from obesity, showcasing ongoing commitment to research and development.

In summary, Wegovy®'s achievement of three million prescriptions in under six months not only symbolizes a transformative moment in the realm of obesity treatment but also speaks volumes about Novo Nordisk's dedication to improving quality of life for patients dealing with obesity. As the healthcare landscape evolves, Wegovy® stands out as a beacon of hope for many who were previously untreated.